MAP2K7 and cancer: RTK−WT RAS signaling supplements basal mutant RAS signaling to fully activate RAF/MEK/ERK and PI3K/AKT effector pathways [50,78] to promote proliferation [50] and G2 checkpoint integrity [79] in RAS-mutated cancer cells.